Literature DB >> 30989369

Motor, cognitive and behavioral differences in MDS PSP phenotypes.

Marina Picillo1, Sofia Cuoco2, Maria Francesca Tepedino2, Arianna Cappiello2, Giampiero Volpe2, Roberto Erro2, Gabriella Santangelo3, Maria Teresa Pellecchia2, Paolo Barone2.   

Abstract

INTRODUCTION: Movement Disorder Society (MDS) new diagnostic criteria for Progressive Supranuclear palsy (PSP) identifying different disease phenotypes were recently released. The aim of the present study is to report on the cognitive and behavioral features of the different phenotypes diagnosed according to the MDS criteria.
METHODS: Forty-nine PSP patients underwent an extensive battery of clinical assessments. Differences between PSP subtypes were computed with χ2 or ANOVA tests. Using the z scores, subjects were classified as having normal cognition, mild cognitive impairment, single or multiple domain, and dementia. A logistic regression model was implemented to investigate the major determinants of PSP non-Richardson's syndrome phenotype.
RESULTS: Half of the cohort presented Richardson's syndrome (46.9%), followed by PSP with parkinsonism and corticobasal syndrome (22.4% and 14.2%, respectively). Richardson's syndrome and PSP with corticobasal syndrome presented a similar burden of disease. The only cognitive testing differentiating the phenotypes were semantic fluency and ideomotor apraxia. The majority of our cohort was either affected by dementia or presented normal cognition. Richardson's syndrome presented the highest rate of dementia. The only marker of PSP non-Richardson's syndrome phenotype was better performance in visuo-spatial testing, implying worse visuo-spatial abilities in PSP Richardson's syndrome.
CONCLUSION: Available clinical assessments hardly capture differences between PSP phenotypes. The cognitive testing differentiating the PSP phenotypes were semantic fluency and ideomotor apraxia. In PSP, mild cognitive impairment likely represents an intermediate step from normal cognition to dementia. The only marker of PSP non-Richardson's syndrome phenotype was better performance in visuo-spatial testing.

Entities:  

Keywords:  Diagnostic criteria; MDS; Progressive supranuclear palsy; Subtype

Year:  2019        PMID: 30989369     DOI: 10.1007/s00415-019-09324-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.

Authors:  Andrea Horta-Barba; Javier Pagonabarraga; Saül Martínez-Horta; Laura Busteed; Berta Pascual-Sedano; Ignacio Illán-Gala; Juan Marin-Lahoz; Ignacio Aracil-Bolaños; Jesús Pérez-Pérez; Frederic Sampedro; Helena Bejr-Kasem; Jaime Kulisevsky
Journal:  J Neurol       Date:  2021-03-11       Impact factor: 4.849

2.  Depression and Apathy across Different Variants of Progressive Supranuclear Palsy.

Authors:  Sarah M Bower; Stephen D Weigand; Farwa Ali; Heather M Clark; Hugo Botha; Julie A Stierwalt; Jennifer L Whitwell; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2021-12-31

3.  Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Authors:  Tien Dam; Adam L Boxer; Lawrence I Golbe; Günter U Höglinger; Huw R Morris; Irene Litvan; Anthony E Lang; Jean-Christophe Corvol; Ikuko Aiba; Michael Grundman; Lili Yang; Beth Tidemann-Miller; Joseph Kupferman; Kristine Harper; Kubra Kamisoglu; Michael J Wald; Danielle L Graham; Liz Gedney; John O'Gorman; Samantha Budd Haeberlein
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

4.  Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.

Authors:  Alexander Pantelyat; Lenora Higginbotham; Liana Rosenthal; Diane Lanham; Vanessa Nesspor; Mina AlSalihi; Jee Bang; Jiangxia Wang; Marilyn Albert
Journal:  Neurodegener Dis       Date:  2021-03-31       Impact factor: 2.977

5.  Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy.

Authors:  Marina Picillo; Filomena Abate; Sara Ponticorvo; Maria Francesca Tepedino; Roberto Erro; Daniela Frosini; Eleonora Del Prete; Paolo Cecchi; Mirco Cosottini; Roberto Ceravolo; Gianfranco Di Salle; Francesco Di Salle; Fabrizio Esposito; Maria Teresa Pellecchia; Renzo Manara; Paolo Barone
Journal:  Front Neurol       Date:  2020-11-12       Impact factor: 4.003

6.  Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy.

Authors:  Sofia Cuoco; Arianna Cappiello; Filomena Abate; Maria Francesca Tepedino; Roberto Erro; Giampiero Volpe; Maria Teresa Pellecchia; Paolo Barone; Marina Picillo
Journal:  Brain Behav       Date:  2021-09-07       Impact factor: 2.708

7.  Energy expenditure, body composition and dietary habits in progressive supranuclear palsy.

Authors:  Marina Picillo; Maria Francesca Tepedino; Maria Claudia Russillo; Filomena Abate; Marta Savastano; Antonio De Simone; Roberto Erro; Maria Teresa Pellecchia; Paolo Barone
Journal:  J Neurol       Date:  2021-10-21       Impact factor: 6.682

8.  Gait Analysis in Progressive Supranuclear Palsy Phenotypes.

Authors:  Marina Picillo; Carlo Ricciardi; Maria Francesca Tepedino; Filomena Abate; Sofia Cuoco; Immacolata Carotenuto; Roberto Erro; Gianluca Ricciardelli; Michela Russo; Mario Cesarelli; Paolo Barone; Marianna Amboni
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

Review 9.  Language impairment in progressive supranuclear palsy and corticobasal syndrome.

Authors:  Katie A Peterson; Karalyn Patterson; James B Rowe
Journal:  J Neurol       Date:  2019-07-18       Impact factor: 4.849

10.  Uncovering clinical and radiological asymmetry in progressive supranuclear palsy-Richardson's syndrome.

Authors:  Marina Picillo; Maria Francesca Tepedino; Filomena Abate; Sara Ponticorvo; Roberto Erro; Sofia Cuoco; Nevra Oksuz; Gianfranco Di Salle; Francesco Di Salle; Fabrizio Esposito; Maria Teresa Pellecchia; Renzo Manara; Paolo Barone
Journal:  Neurol Sci       Date:  2022-02-01       Impact factor: 3.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.